Demystifying Charles River: Insights From 4 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have provided diverse evaluations of Charles River Laboratories (NYSE: CRL), ranging from bullish to bearish. The average 12-month price target has decreased by 5.63% to $255.75. Key analysts have adjusted their ratings and price targets, reflecting varied perspectives on the company's future performance.
June 28, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Charles River Laboratories has received mixed analyst ratings over the past three months, with an average 12-month price target now at $255.75, down from $271.00. Key analysts have adjusted their ratings and price targets, reflecting varied perspectives on the company's future performance.
The mixed analyst ratings and the decrease in the average price target suggest uncertainty about Charles River's short-term performance. While some analysts are bullish, others have lowered their ratings and price targets, indicating a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100